Arcutis biotherapeutics stock.

Jun 9, 2023 · Shares of Arcutis Biotherapeutics ( ARQT -3.16%) climbed 21.2% for the week after rising as high as 23.8%, according to data provided by S&P Global Market Intelligence. The medical dermatology ... Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a medical dermatology company that champions meaningful innovation to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis harnesses our unique ...0.50%. ¥2.18T. ARQT | Complete Arcutis Biotherapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. 9 analysts have issued twelve-month target prices for Arcutis Biotherapeutics' shares. Their ARQT share price targets range from $6.00 to $57.00. On average, they anticipate the company's stock price to reach $29.67 in the next year. This suggests a possible upside of 1,390.8% from the stock's current price.

WESTLAKE VILLAGE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (“Arcutis”) (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the pricing of its underwritten public offering of 7,500,000 shares of its common stock at a public offering price of $20.00 per share ...Arcutis Biotherapeutics, Inc. is a medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions.

Arcutis Biotherapeutics stock price forecast: $51; Market Cap: 179.32M, Enterprise value: 934.67M, P/E: -2.1, PEG ratio: 0.05, EPS: -4.43, Revenue: 49.04M, ...Stock Quote & Chart. Change. Volume. Today's Open. Previous Close. Today's High. Today's Low. 52 Week High.

Phone Number 805-418-5006. Arcutis Biotherapeutics is a privately held clinical-stage biopharmaceutical company focused on developing and commercializing treatments for …Review Arcutis Biotherapeutics Inc Ordinary Shares (ARQT:XNAS) stock's current information regarding return on assets, equity, invested capital, margins, and turnover over the last fiscal year.Mar 18, 2023 · WESTLAKE VILLAGE, Calif., March 18, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today presented in a late-breaking clinical trial session at the American Academy of Dermatology (AAD) annual meeting (New Orleans, LA ... Arcutis Biotherapeutics, Inc. is a medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions.

Discover historical prices for ARQT stock on Yahoo Finance. View daily, weekly or monthly format back to when Arcutis Biotherapeutics, Inc. stock was issued.

Track Arcutis Biotherapeutics Inc (ARQT) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors

The stock options have a ten-year term and an exercise price of $1.99 per share, equal to the per share closing price of Arcutis’ common stock as reported by Nasdaq on December 1, 2023.Arcutis Biotherapeutics (ARQT) Stock Price, News & Info | The Motley Fool Arcutis Biotherapeutics (NASDAQ: ARQT) $2.20 (-6.4%) -$0.15 Price as of November 8, 2023, 4:00 p.m. ET Overview...Bioscience, applied to the skin. | Arcutis is addressing the innovation gap in medical #dermatology drug development. $ARQT #DermTwitter #Immunodermatology.Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is an early commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of patients living with ...Health Technology. Industry. Pharmaceuticals: Major. No executives to display. Corporate headquarters. --, --. Find real-time ARQT - Arcutis Biotherapeutics Inc stock quotes, company profile, news ... Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.

WESTLAKE VILLAGE, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) (“Arcutis”), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the pricing of its underwritten public offering of common …Currently, Arcutis Biotherapeutics has an average volume of 1.07M. Based on the recent corporate insider activity of 47 insiders, corporate insider sentiment is negative on the stock.Arcutis is building momentum around its Zoryve segment with a string of recent advancements at the back end of FY22 and into the new year. Find out why ARQT stock is a Buy.WESTLAKE VILLAGE, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (“Arcutis”) (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, …WESTLAKE VILLAGE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (“Arcutis”) (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the pricing of its underwritten public offering of 7,500,000 shares of its common stock at a public offering price of $20.00 per share ... Arcutis Biotherapeutics, Inc. (ARQT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall ...

As of March 29, 2023, 4:00 PM CST, Arcutis Biotherapeutics Inc’s stock price was $10.71. Arcutis Biotherapeutics Inc is up 4.59% from its previous closing price of $10.24. During the last market session, Arcutis Biotherapeutics Inc’s stock traded between $10.19 and $10.70. Currently, there are 61.04 million shares of Arcutis Biotherapeutics ...

May 10, 2023 1:55 PM ET Arcutis Biotherapeutics, Inc. (ARQT) By: Jonathan Block, SA News Editor. CharlieAJA. Arcutis Biotherapeutics ( NASDAQ: ARQT) is down ~20% in Wednesday afternoon trading ...Stock Quote & Chart. Change. Volume. Today's Open. Previous Close. Today's High. Today's Low. 52 Week High. 52 Week Low.In addition, Arcutis has granted the underwriters a 30-day option to purchase up to an additional 1,125,000 shares of common stock at the public offering price, less underwriting discounts and ...Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is an early commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with ...Complete Arcutis Biotherapeutics Inc. stock information by Barron's. View real-time ARQT stock price and news, along with industry-best analysis. Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is an early commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with ...A Different Perspective. Arcutis Biotherapeutics shareholders may not have made money over the last year, but their total loss of 5.5% isn't as bad as the market loss of around 5.5%.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is an early commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of patients living with ...

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated ...

Company profile page for Arcutis Biotherapeutics Inc including stock price, company news, executives, board members, and contact informationView the latest Arcutis Biotherapeutics Inc. (ARQT) stock price, news, historical charts, analyst ratings and financial information from WSJ. On Wednesday, Arcutis Biotherapeutics Inc [NASDAQ: ARQT] plunged -4.59% to $2.08. The stock’s lowest price that day was $2.07, but it reached a high of $2.33 in the same session. During the last five days, there has been a drop of approximately -5.45%. Over the course of the year, Arcutis Biotherapeutics Inc shares have dropped approximately ...August 8, 2023 at 4:02 PM · 11 min read. Arcutis Biotherapeutics, Inc. Achieved total revenues of $5.2 million in the second quarter of 2023. Net product revenues for ZORYVE® (roflumilast) cream ...These 8 analysts have an average price target of $25.62 versus the current price of Arcutis Biotherapeutics at $2.49, implying upside. Below is a summary of how these 8 analysts rated Arcutis ...In addition, Arcutis has granted the underwriters a 30-day option to purchase up to an additional 1,125,000 shares of common stock at the public offering price, less …Oct. 9, 2023, 08:27 AM Sean Kim PhD, an analyst from JonesTrading, reiterated the Buy rating on Arcutis Biotherapeutics ( ARQT – Research Report ). The associated price target is $44.00. Sean...Stock Price Forecast. The 7 analysts offering 12-month price forecasts for Arcutis Biotherapeutics Inc have a median target of 10.00, with a high estimate of ...These 8 analysts have an average price target of $25.62 versus the current price of Arcutis Biotherapeutics at $2.49, implying upside. Below is a summary of how these 8 analysts rated Arcutis ...Arcutis Biotherapeutics Inc is down 6.97% from its previous closing price of $7.82. During the last market session, Arcutis Biotherapeutics Inc’s stock traded between $7.82 and $8.26. Currently, there are 61.43 million shares of Arcutis Biotherapeutics Inc stock available for purchase. Unfortunately, Arcutis Biotherapeutics Inc’s P/E ratio ...Arcutis Biotherapeutics, Inc. Common Stock (ARQT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Stock analysis for Arcutis Biotherapeutics Inc (ARQT:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Earnings for Arcutis Biotherapeutics are expected to grow in the coming year, from ($3.78) to ($2.65) per share. Arcutis Biotherapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 27th, 2024 based off prior year's report dates.About Arcutis . Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is an early commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in …Arcutis Biotherapeutics has received a new Buy rating, initiated by Mizuho Securities analyst, Uy Ear.Uy Ear’s rating for Arcutis Biotherapeutics is based on several crucial factors. One of the ...Instagram:https://instagram. best day trading stocksanti semticis nvidia overvaluednyse mt Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated ... o dividendsthor manufacturing Health Technology. Industry. Pharmaceuticals: Major. No executives to display. Corporate headquarters. --, --. Find real-time ARQT - Arcutis Biotherapeutics Inc stock quotes, company profile, news ... invest in senior housing View All The Investor Relations website contains information about Arcutis Biotherapeutics's business for stockholders, potential investors, and financial analysts.Shares of Arcutis Biotherapeutics ... The healthcare company's stock closed last week at $8.96 a share and fell to as low as $7.47 on Thursday after Arcutis reported trial data regarding a ...